Hint mode is switched on Switch off
For swift navigation between sections

Regen Biopharma
LEI 549300S6GNPDQ0F5FT79

PDF download

Choose all Reset all
Download Cancel
Organization name
Regen Biopharma, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Regen Biopharma, Inc. is a biotechnology company. The Company is focused on identifying regenerative medicine applications in the stem cell/immunotherapy space and advancing these technologies through pre-clinical and Phase I/II clinical trials. The Company is developing products treating blood disorders using small molecules and gene silencing, treating cancer with immunotherapy, modulating molecular processes in cancer stem cell through its molecular targeting approaches, and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients.

Awards

News

10/07/2026 Regen Biopharma: (entry Into A Material Definitive Agreement), Other Events, Financial Statements And Exhibits
19/01/2026 Regen Biopharma: Other Events
15/01/2026 Regen Biopharma: Unregistered Sales Of Equity Securities
02/10/2025 Regen Biopharma: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And Exhibits
28/07/2025 Regen Biopharma: Entry Into A Material Definitive Agreement, Recent Sales Of Unregistered Securities, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300S6GNPDQ0F5FT79
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001589150
Registration is required to get access.